News

Activinsights and Cardialysis Announce a New Strategic Partnership

| Activinsights News, Press Releases

Activinsights is excited to announce a new partnership agreement with Cardialysis, a leading Cardiovascular Research Organisation with an exclusive focus on cardiology.

This new collaboration will see Cardialysis become the first organisation of its kind to promote the use of remote monitoring wearables as a tool for researchers to better understand the daily lifestyles of their patients.

By using Activinsights’ professional wearable devices, Cardialysis will be able to accurately understand their patient’s behaviours and monitor behaviours such as sleep, sedentary behaviour, walking and high activity levels, as related to cardiology. By collecting this in-depth raw data, sponsors will be able to analyse and understand how certain treatments and interventions may be affecting the patient.

Dr. Ernest Spitzer, Chief Medical Officer at Cardialysis commented, “The use of professional wearables in clinical research brings us a step closer to understanding how new therapies effect the day-to-day symptoms of trial participants. As much as traditional clinical outcomes remain a priority for effectiveness and safety assessments, incorporating actigraphy into clinical research may become a new standard for the short and mid-term evaluation of cardiovascular therapies”.

An active lifestyle is pivotal to remaining healthy and is important for smooth recovery after periods of disease. In cardiology, however, most conditions are chronic, meaning that once a patient is diagnosed, the disease will progress unless treated. These cardiac conditions may affect the patient’s ability to exercise or even perform daily activities. Therapies based on devices or drugs can improve symptoms and quality of life, and actigraphy is a modern method to assess these changes.

“Three conditions where the use of actigraphy becomes immediately evident are heart failure, structural heart disease, and coronary artery disease, especially in comparisons between surgical and transcatheter interventions,” commented Dr. Spitzer.

Bill Hogan, Activinsights’ CEO also expressed his delight in this new partnership – “We are very excited about this collaboration. The opportunity to work with Cardialysis to offer our professional wearables will be of huge value to clinicians and researchers as they assess patient behaviours. With the move towards decentralised trials accelerating, patient remote monitoring is now critical, particularly for long-term deployment, so this relationship will be significant to cardiology patients going forward”.

Activinsights’ technologies have been successfully deployed within cardiology trials and studies for many years. This collaboration between Cardialysis and Activinsights supports trials in gaining additional objective digital measures outside of the clinical environment. The ability to understand a patient’s quality of life remotely, along with supporting clinical endpoints such as the 6-minute walk test in a free-living environment, will continue to innovate the market. Activinsights’ high-quality data goes beyond traditional actigraphy and enables the development of relevant digital biomarkers within cardiovascular disease research.

This partnership steers towards an exciting future in supporting cardiology trials, with an overall goal to improve health outcomes for many patients.

____________

About Cardialysis
Cardialysis is a leading Cardiovascular Research Organization with an exclusive focus on cardiology, providing the full range of clinical research and cardiovascular core laboratory services. Through almost 40 years, Cardialysis has executed over 400 clinical investigations, and contributed to advances in the management of cardiovascular disease ultimately improving clinical outcomes and quality of life. Its largest contribution relates to clinical investigations with cardiovascular devices, such as coronary stents and transcatheter heart valves; nevertheless, the organization has also managed some of the largest and most innovative drug trials in interventional cardiology and heart failure. Cardialysis is recognized for its key-opinion-leader network, strong academic involvement, and in-depth methodological expertise. In the past decades, Cardialysis has developed full-service clinical operations capabilities, which in combination with its academic and core laboratory services, allow to plan and execute a clinical investigation from the design phase up to the reporting of the study results.

About Activinsights
Activinsights is a digital health company that specialises in the objective measurement of physical behaviours and lifestyle. Our technologies are used worldwide within the clinical trials, health management and research markets to provide accurate and continuous monitoring of lifestyle outside of the clinic environment. We develop novel health measures from data collected by our own professional wearables and other connected devices, such as phone apps, within a scalable global and secure infrastructure. Advanced data analytics reveal insights, novel endpoints and biomarkers that support pharmaceutical drug development, clinical practice, and disease management.

For more information, contact:
Raghbir Bains PhD
Commercial Director, Activinsights
[email protected]
+44 (0)7496 292 073

Forthcoming Events

  • Jun 2022   Decentralized Clinical Trials 2022, Florida, USA
  • Jun 2022   ICAMPAM 2022, Colorado, USA
  • Jun 2022   Digital Biomarkers & Digital Measurements Summit Europe, London, UK

View all events